Evidence map›Paper›PMID 27035987›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.

Aleidy Silva, Bai-Yu Lee, Daniel L Clemens, Theodore Kee, Xianting Ding, Chih-Ming Ho, Marcus A Horwitz

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03561753 phase4completednot on this mapstarted 2017, after this paper: background citation

Pilot Clinical Trial of PRS TB Regimen I - Phase II

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2017 to 2020Enrolled97ConditionsPulmonary Tuberculosis TB in Sputum: (+) MicroscopyArmsGroup A (the standard 2HRZE/4HR regimen), Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
NCT05278988 phase4completednot on this mapstarted 2021, after this paper: background citation

A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2021 to 2024Enrolled60ConditionsMDR-TBArmsPRS Regimen V, MDR-TB Treatment Regimen(WHO)
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Clofazimine for the treatment of tuberculosis.Frontiers in pharmacology · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Aleidy SilvaDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA 90095;
Bai-Yu LeeDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA 90095;
Daniel L ClemensDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA 90095;
Theodore KeeDepartment of Bioengineering, University of California, Los Angeles, CA 90095;
Xianting DingMed-X Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Chih-Ming HoDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA 90095; Department of Bioengineering, University of California, Los Angeles, CA 90095; chihming@g.ucla.edu MHorwitz@mednet.ucla.edu.
Marcus A HorwitzDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA 90095; chihming@g.ucla.edu MHorwitz@mednet.ucla.edu.
University of California, Los Angeles · USShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a major global public health problem, and improved treatments are needed to shorten duration of therapy, decrease disease burden, improve compliance, and combat emergence of drug resistance. Ideally, the most effective regimen would be identified by a systematic and comprehensive combinatorial search of large numbers of TB drugs. However, optimization of regimens by standard methods is challenging, especially as the number of drugs increases, because of the extremely large number of drug-dose combinations requiring testing. Herein, we used an optimization platform, feedback system control (FSC) methodology, to identify improved drug-dose combinations for TB treatment using a fluorescence-based human macrophage cell culture model of TB, in which macrophages are infected with isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible green fluorescent protein (GFP)-expressing Mycobacterium tuberculosis (Mtb). On the basis of only a single screening test and three iterations, we identified highly efficacious three- and four-drug combinations. To verify the efficacy of these combinations, we further evaluated them using a methodologically independent assay for intramacrophage killing of Mtb; the optimized combinations showed greater efficacy than the current standard TB drug regimen. Surprisingly, all top three- and four-drug optimized regimens included the third-line drug clofazimine, and none included the first-line drugs isoniazid and rifampin, which had insignificant or antagonistic impacts on efficacy. Because top regimens also did not include a fluoroquinolone or aminoglycoside, they are potentially of use for treating many cases of multidrug- and extensively drug-resistant TB. Our study shows the power of an FSC platform to identify promising previously unidentified drug-dose combinations for treatment of TB.

Indexed as

Antitubercular AgentsCell LineCells, CulturedDrug CombinationsDrug InteractionsFeedbackGreen Fluorescent ProteinsHigh-Throughput Screening AssaysHumansIsopropyl ThiogalactosideMacrophagesMycobacterium tuberculosisTuberculosisAntitubercular AgentsDrug CombinationsGreen Fluorescent ProteinsIsopropyl Thiogalactosidedrug combination optimizationfeedback system controlMycobacterium tuberculosistuberculosis

Identifiers

PMID27035987
PMCPMC4839402
OpenAlexW2312325831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.